nodes	percent_of_prediction	percent_of_DWPC	metapath
Isoprenaline—CYP1A1—Dacarbazine—skin cancer	0.0219	1	CbGbCtD
Isoprenaline—MAPK1—hair follicle—skin cancer	0.0165	0.0804	CbGeAlD
Isoprenaline—PIK3R1—nipple—skin cancer	0.0164	0.0799	CbGeAlD
Isoprenaline—PIK3R2—female reproductive system—skin cancer	0.0142	0.0689	CbGeAlD
Isoprenaline—PIK3R2—head—skin cancer	0.0119	0.0576	CbGeAlD
Isoprenaline—PIK3R3—female reproductive system—skin cancer	0.00963	0.0468	CbGeAlD
Isoprenaline—PIK3R1—mammalian vulva—skin cancer	0.0096	0.0467	CbGeAlD
Isoprenaline—ADRB3—connective tissue—skin cancer	0.00825	0.0401	CbGeAlD
Isoprenaline—PIK3R3—head—skin cancer	0.00804	0.0391	CbGeAlD
Isoprenaline—MAPK1—connective tissue—skin cancer	0.00795	0.0386	CbGeAlD
Isoprenaline—MAPK1—epithelium—skin cancer	0.00755	0.0367	CbGeAlD
Isoprenaline—MAPK1—skin of body—skin cancer	0.00718	0.0349	CbGeAlD
Isoprenaline—MAPK1—mammalian vulva—skin cancer	0.00655	0.0318	CbGeAlD
Isoprenaline—CYP1A1—skin epidermis—skin cancer	0.00634	0.0308	CbGeAlD
Isoprenaline—ADRBK1—lymphoid tissue—skin cancer	0.0059	0.0287	CbGeAlD
Isoprenaline—ADRB3—female reproductive system—skin cancer	0.00582	0.0283	CbGeAlD
Isoprenaline—MAPK1—lymphoid tissue—skin cancer	0.00581	0.0283	CbGeAlD
Isoprenaline—ADRBK1—female reproductive system—skin cancer	0.00569	0.0277	CbGeAlD
Isoprenaline—PIK3R3—lymph node—skin cancer	0.00563	0.0274	CbGeAlD
Isoprenaline—MAPK1—female reproductive system—skin cancer	0.00561	0.0273	CbGeAlD
Isoprenaline—PIK3R1—lymph node—skin cancer	0.00481	0.0234	CbGeAlD
Isoprenaline—ADRBK1—head—skin cancer	0.00475	0.0231	CbGeAlD
Isoprenaline—MAPK1—head—skin cancer	0.00468	0.0228	CbGeAlD
Isoprenaline—ADRB1—connective tissue—skin cancer	0.00337	0.0164	CbGeAlD
Isoprenaline—ADRBK1—lymph node—skin cancer	0.00333	0.0162	CbGeAlD
Isoprenaline—MAPK1—lymph node—skin cancer	0.00328	0.0159	CbGeAlD
Isoprenaline—CYP1A1—nipple—skin cancer	0.00307	0.0149	CbGeAlD
Isoprenaline—ADRB1—female reproductive system—skin cancer	0.00238	0.0116	CbGeAlD
Isoprenaline—CYP1A1—epithelium—skin cancer	0.00207	0.01	CbGeAlD
Isoprenaline—ADRB1—head—skin cancer	0.00199	0.00966	CbGeAlD
Isoprenaline—CYP1A1—skin of body—skin cancer	0.00197	0.00955	CbGeAlD
Isoprenaline—CYP1A1—mammalian vulva—skin cancer	0.00179	0.00871	CbGeAlD
Isoprenaline—CYP1A1—female reproductive system—skin cancer	0.00153	0.00746	CbGeAlD
Isoprenaline—Pulmonary oedema—Imiquimod—skin cancer	0.00151	0.0504	CcSEcCtD
Isoprenaline—CYP1A1—head—skin cancer	0.00128	0.00623	CbGeAlD
Isoprenaline—CYP1A1—lymph node—skin cancer	0.000898	0.00436	CbGeAlD
Isoprenaline—Asthenia—Vismodegib—skin cancer	0.000822	0.0275	CcSEcCtD
Isoprenaline—Flushing—Imiquimod—skin cancer	0.000789	0.0264	CcSEcCtD
Isoprenaline—Arrhythmia—Imiquimod—skin cancer	0.000759	0.0254	CcSEcCtD
Isoprenaline—Bronchospasm—Bleomycin—skin cancer	0.000742	0.0248	CcSEcCtD
Isoprenaline—Nausea—Vismodegib—skin cancer	0.000681	0.0228	CcSEcCtD
Isoprenaline—Hypotension—Vemurafenib—skin cancer	0.000661	0.0221	CcSEcCtD
Isoprenaline—Palpitations—Imiquimod—skin cancer	0.000654	0.0219	CcSEcCtD
Isoprenaline—Cardiac arrest—Fluorouracil—skin cancer	0.000645	0.0216	CcSEcCtD
Isoprenaline—Convulsion—Imiquimod—skin cancer	0.000641	0.0214	CcSEcCtD
Isoprenaline—Hypertension—Imiquimod—skin cancer	0.000639	0.0214	CcSEcCtD
Isoprenaline—Pulmonary oedema—Docetaxel—skin cancer	0.0006	0.0201	CcSEcCtD
Isoprenaline—Tachycardia—Imiquimod—skin cancer	0.000589	0.0197	CcSEcCtD
Isoprenaline—Hyperhidrosis—Imiquimod—skin cancer	0.000584	0.0195	CcSEcCtD
Isoprenaline—Angina pectoris—Fluorouracil—skin cancer	0.000571	0.0191	CcSEcCtD
Isoprenaline—Flushing—Bleomycin—skin cancer	0.00056	0.0187	CcSEcCtD
Isoprenaline—Insomnia—Imiquimod—skin cancer	0.000546	0.0183	CcSEcCtD
Isoprenaline—Dyspnoea—Imiquimod—skin cancer	0.000538	0.018	CcSEcCtD
Isoprenaline—Flushing—Dactinomycin—skin cancer	0.000522	0.0175	CcSEcCtD
Isoprenaline—Asthenia—Vemurafenib—skin cancer	0.000508	0.017	CcSEcCtD
Isoprenaline—Flushing—Temozolomide—skin cancer	0.000473	0.0158	CcSEcCtD
Isoprenaline—Dizziness—Vemurafenib—skin cancer	0.000468	0.0157	CcSEcCtD
Isoprenaline—Headache—Vemurafenib—skin cancer	0.000443	0.0148	CcSEcCtD
Isoprenaline—Asthenia—Imiquimod—skin cancer	0.000433	0.0145	CcSEcCtD
Isoprenaline—Nausea—Vemurafenib—skin cancer	0.00042	0.0141	CcSEcCtD
Isoprenaline—Arrhythmia—Fluorouracil—skin cancer	0.000419	0.014	CcSEcCtD
Isoprenaline—Vision blurred—Temozolomide—skin cancer	0.000418	0.014	CcSEcCtD
Isoprenaline—Bronchospasm—Docetaxel—skin cancer	0.000416	0.0139	CcSEcCtD
Isoprenaline—Tremor—Temozolomide—skin cancer	0.000415	0.0139	CcSEcCtD
Isoprenaline—Angina pectoris—Docetaxel—skin cancer	0.000412	0.0138	CcSEcCtD
Isoprenaline—Hypotension—Bleomycin—skin cancer	0.000401	0.0134	CcSEcCtD
Isoprenaline—Dizziness—Imiquimod—skin cancer	0.000399	0.0134	CcSEcCtD
Isoprenaline—Vertigo—Temozolomide—skin cancer	0.000398	0.0133	CcSEcCtD
Isoprenaline—Palpitations—Temozolomide—skin cancer	0.000392	0.0131	CcSEcCtD
Isoprenaline—Vision blurred—Fluorouracil—skin cancer	0.000385	0.0129	CcSEcCtD
Isoprenaline—Convulsion—Temozolomide—skin cancer	0.000384	0.0129	CcSEcCtD
Isoprenaline—Hypertension—Temozolomide—skin cancer	0.000383	0.0128	CcSEcCtD
Isoprenaline—Dyspnoea—Bleomycin—skin cancer	0.000382	0.0128	CcSEcCtD
Isoprenaline—Headache—Imiquimod—skin cancer	0.000378	0.0127	CcSEcCtD
Isoprenaline—Nausea—Imiquimod—skin cancer	0.000359	0.012	CcSEcCtD
Isoprenaline—Convulsion—Fluorouracil—skin cancer	0.000354	0.0118	CcSEcCtD
Isoprenaline—Hyperhidrosis—Temozolomide—skin cancer	0.00035	0.0117	CcSEcCtD
Isoprenaline—Insomnia—Temozolomide—skin cancer	0.000327	0.011	CcSEcCtD
Isoprenaline—Tachycardia—Fluorouracil—skin cancer	0.000325	0.0109	CcSEcCtD
Isoprenaline—Dyspnoea—Temozolomide—skin cancer	0.000323	0.0108	CcSEcCtD
Isoprenaline—Flushing—Docetaxel—skin cancer	0.000314	0.0105	CcSEcCtD
Isoprenaline—Hypotension—Fluorouracil—skin cancer	0.000311	0.0104	CcSEcCtD
Isoprenaline—Asthenia—Bleomycin—skin cancer	0.000308	0.0103	CcSEcCtD
Isoprenaline—Arrhythmia—Docetaxel—skin cancer	0.000302	0.0101	CcSEcCtD
Isoprenaline—Insomnia—Fluorouracil—skin cancer	0.000301	0.0101	CcSEcCtD
Isoprenaline—Dyspnoea—Fluorouracil—skin cancer	0.000297	0.00995	CcSEcCtD
Isoprenaline—Asthenia—Dactinomycin—skin cancer	0.000287	0.0096	CcSEcCtD
Isoprenaline—Palpitations—Docetaxel—skin cancer	0.00026	0.00872	CcSEcCtD
Isoprenaline—Asthenia—Temozolomide—skin cancer	0.00026	0.00869	CcSEcCtD
Isoprenaline—Convulsion—Docetaxel—skin cancer	0.000255	0.00855	CcSEcCtD
Isoprenaline—Nausea—Bleomycin—skin cancer	0.000255	0.00853	CcSEcCtD
Isoprenaline—Hypertension—Docetaxel—skin cancer	0.000254	0.00852	CcSEcCtD
Isoprenaline—Dizziness—Temozolomide—skin cancer	0.000239	0.00801	CcSEcCtD
Isoprenaline—Nausea—Dactinomycin—skin cancer	0.000238	0.00795	CcSEcCtD
Isoprenaline—Tachycardia—Docetaxel—skin cancer	0.000235	0.00786	CcSEcCtD
Isoprenaline—Headache—Temozolomide—skin cancer	0.000227	0.00758	CcSEcCtD
Isoprenaline—Hypotension—Docetaxel—skin cancer	0.000225	0.00752	CcSEcCtD
Isoprenaline—Dizziness—Fluorouracil—skin cancer	0.00022	0.00738	CcSEcCtD
Isoprenaline—Insomnia—Docetaxel—skin cancer	0.000218	0.00728	CcSEcCtD
Isoprenaline—Nausea—Temozolomide—skin cancer	0.000215	0.00719	CcSEcCtD
Isoprenaline—Dyspnoea—Docetaxel—skin cancer	0.000214	0.00718	CcSEcCtD
Isoprenaline—Headache—Fluorouracil—skin cancer	0.000209	0.00699	CcSEcCtD
Isoprenaline—Nausea—Fluorouracil—skin cancer	0.000198	0.00663	CcSEcCtD
Isoprenaline—Asthenia—Docetaxel—skin cancer	0.000173	0.00578	CcSEcCtD
Isoprenaline—Dizziness—Docetaxel—skin cancer	0.000159	0.00532	CcSEcCtD
Isoprenaline—Headache—Docetaxel—skin cancer	0.000151	0.00504	CcSEcCtD
Isoprenaline—Nausea—Docetaxel—skin cancer	0.000143	0.00478	CcSEcCtD
Isoprenaline—MAPK1—DAP12 interactions—IL6—skin cancer	9.68e-05	0.00013	CbGpPWpGaD
Isoprenaline—ADRBK1—Innate Immune System—NRAS—skin cancer	9.61e-05	0.000129	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by EGFR—IL6—skin cancer	9.6e-05	0.000129	CbGpPWpGaD
Isoprenaline—MAPK1—Cytokine Signaling in Immune system—NRAS—skin cancer	9.58e-05	0.000129	CbGpPWpGaD
Isoprenaline—MAPK1—Focal Adhesion—HRAS—skin cancer	9.56e-05	0.000129	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by EGFR in Cancer—IL6—skin cancer	9.51e-05	0.000128	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by PDGF—IL6—skin cancer	9.47e-05	0.000128	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by NGF—NRAS—skin cancer	9.42e-05	0.000127	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—ERCC2—skin cancer	9.42e-05	0.000127	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—FOXO4—skin cancer	9.41e-05	0.000127	CbGpPWpGaD
Isoprenaline—PIK3R2—Adaptive Immune System—NRAS—skin cancer	9.37e-05	0.000126	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—GLI2—skin cancer	9.36e-05	0.000126	CbGpPWpGaD
Isoprenaline—PIK3R2—Hemostasis—KRAS—skin cancer	9.33e-05	0.000126	CbGpPWpGaD
Isoprenaline—MAPK1—Cellular Senescence—IL6—skin cancer	9.31e-05	0.000125	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—TERT—skin cancer	9.26e-05	0.000125	CbGpPWpGaD
Isoprenaline—MAPK1—Transmission across Chemical Synapses—HRAS—skin cancer	9.17e-05	0.000124	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—GLI2—skin cancer	9.16e-05	0.000123	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—ERCC2—skin cancer	9.11e-05	0.000123	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PLIN2—skin cancer	9.04e-05	0.000122	CbGpPWpGaD
Isoprenaline—MAPK1—NGF signalling via TRKA from the plasma membrane—HRAS—skin cancer	8.96e-05	0.000121	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—FOXO4—skin cancer	8.95e-05	0.000121	CbGpPWpGaD
Isoprenaline—PIK3R3—Innate Immune System—HRAS—skin cancer	8.95e-05	0.000121	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—MC1R—skin cancer	8.93e-05	0.00012	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—GLI1—skin cancer	8.8e-05	0.000119	CbGpPWpGaD
Isoprenaline—PIK3R1—Hemostasis—NRAS—skin cancer	8.78e-05	0.000118	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—FOXO4—skin cancer	8.74e-05	0.000118	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—MC1R—skin cancer	8.74e-05	0.000118	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—FOXO4—skin cancer	8.69e-05	0.000117	CbGpPWpGaD
Isoprenaline—MAPK1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—skin cancer	8.66e-05	0.000117	CbGpPWpGaD
Isoprenaline—MAPK1—Cell Cycle, Mitotic—CDKN2A—skin cancer	8.66e-05	0.000117	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—GLI1—skin cancer	8.61e-05	0.000116	CbGpPWpGaD
Isoprenaline—PIK3R3—Adaptive Immune System—HRAS—skin cancer	8.6e-05	0.000116	CbGpPWpGaD
Isoprenaline—MAPK1—NGF signalling via TRKA from the plasma membrane—IL6—skin cancer	8.58e-05	0.000116	CbGpPWpGaD
Isoprenaline—PIK3R3—Innate Immune System—IL6—skin cancer	8.57e-05	0.000115	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—TERT—skin cancer	8.54e-05	0.000115	CbGpPWpGaD
Isoprenaline—MAPK1—Axon guidance—NRAS—skin cancer	8.53e-05	0.000115	CbGpPWpGaD
Isoprenaline—PIK3R3—Disease—PTGS2—skin cancer	8.46e-05	0.000114	CbGpPWpGaD
Isoprenaline—PIK3R2—Innate Immune System—KRAS—skin cancer	8.4e-05	0.000113	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—BRAF—skin cancer	8.35e-05	0.000112	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SUFU—skin cancer	8.34e-05	0.000112	CbGpPWpGaD
Isoprenaline—PIK3R2—Hemostasis—TP53—skin cancer	8.29e-05	0.000112	CbGpPWpGaD
Isoprenaline—MAPK1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—skin cancer	8.29e-05	0.000112	CbGpPWpGaD
Isoprenaline—ADRBK1—Innate Immune System—KRAS—skin cancer	8.27e-05	0.000111	CbGpPWpGaD
Isoprenaline—MAPK1—Cytokine Signaling in Immune system—KRAS—skin cancer	8.25e-05	0.000111	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—BRAF—skin cancer	8.22e-05	0.000111	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SUFU—skin cancer	8.16e-05	0.00011	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by NGF—KRAS—skin cancer	8.11e-05	0.000109	CbGpPWpGaD
Isoprenaline—PIK3R2—Adaptive Immune System—KRAS—skin cancer	8.06e-05	0.000109	CbGpPWpGaD
Isoprenaline—PIK3R2—Hemostasis—HRAS—skin cancer	7.93e-05	0.000107	CbGpPWpGaD
Isoprenaline—PIK3R1—Innate Immune System—NRAS—skin cancer	7.9e-05	0.000106	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling by GPCR—NRAS—skin cancer	7.8e-05	0.000105	CbGpPWpGaD
Isoprenaline—MAPK1—Cell Cycle—CDKN2A—skin cancer	7.74e-05	0.000104	CbGpPWpGaD
Isoprenaline—MAPK1—Cellular responses to stress—TP53—skin cancer	7.68e-05	0.000103	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—ERCC2—skin cancer	7.63e-05	0.000103	CbGpPWpGaD
Isoprenaline—PIK3R1—Adaptive Immune System—NRAS—skin cancer	7.59e-05	0.000102	CbGpPWpGaD
Isoprenaline—PIK3R1—Hemostasis—KRAS—skin cancer	7.56e-05	0.000102	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SHH—skin cancer	7.47e-05	0.000101	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—RASA1—skin cancer	7.42e-05	9.99e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TERT—skin cancer	7.38e-05	9.94e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Axon guidance—KRAS—skin cancer	7.34e-05	9.88e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—BRAF—skin cancer	7.33e-05	9.88e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—CSPG4—skin cancer	7.29e-05	9.81e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TERT—skin cancer	7.27e-05	9.79e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Innate Immune System—HRAS—skin cancer	7.14e-05	9.61e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Immune System—NRAS—skin cancer	7.13e-05	9.6e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Metabolism—PTGS2—skin cancer	7.08e-05	9.54e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—SMO—skin cancer	7.08e-05	9.53e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PTCH1—skin cancer	7.08e-05	9.53e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Cellular responses to stress—IL6—skin cancer	7.03e-05	9.47e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Innate Immune System—HRAS—skin cancer	7.03e-05	9.47e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Neuronal System—HRAS—skin cancer	7.03e-05	9.47e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Cytokine Signaling in Immune system—HRAS—skin cancer	7.01e-05	9.44e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by NGF—HRAS—skin cancer	6.89e-05	9.28e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—PTGER4—skin cancer	6.89e-05	9.28e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Adaptive Immune System—HRAS—skin cancer	6.85e-05	9.23e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Innate Immune System—IL6—skin cancer	6.83e-05	9.2e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Innate Immune System—KRAS—skin cancer	6.8e-05	9.16e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—BRAF—skin cancer	6.76e-05	9.11e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—PTGS2—skin cancer	6.74e-05	9.08e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Innate Immune System—IL6—skin cancer	6.73e-05	9.06e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Hemostasis—TP53—skin cancer	6.72e-05	9.05e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling by GPCR—KRAS—skin cancer	6.71e-05	9.04e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Cytokine Signaling in Immune system—IL6—skin cancer	6.71e-05	9.04e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—PTGS2—skin cancer	6.64e-05	8.95e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by NGF—IL6—skin cancer	6.6e-05	8.88e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Disease—NRAS—skin cancer	6.58e-05	8.86e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Adaptive Immune System—KRAS—skin cancer	6.53e-05	8.8e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Hemostasis—HRAS—skin cancer	6.42e-05	8.65e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SHH—skin cancer	6.36e-05	8.57e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—RASA1—skin cancer	6.32e-05	8.52e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Axon guidance—HRAS—skin cancer	6.24e-05	8.4e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SHH—skin cancer	6.22e-05	8.38e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling by GPCR—NRAS—skin cancer	6.22e-05	8.38e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—ERCC2—skin cancer	6.19e-05	8.34e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—RASA1—skin cancer	6.19e-05	8.33e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Immune System—KRAS—skin cancer	6.13e-05	8.26e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling by GPCR—NRAS—skin cancer	6.13e-05	8.25e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—FOXO4—skin cancer	6.09e-05	8.2e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—NRAS—skin cancer	6.08e-05	8.19e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—SMO—skin cancer	6.03e-05	8.12e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PTCH1—skin cancer	6.03e-05	8.12e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TERT—skin cancer	5.98e-05	8.05e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Axon guidance—IL6—skin cancer	5.97e-05	8.04e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—NRAS—skin cancer	5.97e-05	8.04e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PTCH1—skin cancer	5.9e-05	7.95e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—SMO—skin cancer	5.9e-05	7.95e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—PTGER4—skin cancer	5.87e-05	7.91e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—BRAF—skin cancer	5.85e-05	7.87e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TERT—skin cancer	5.84e-05	7.86e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—TERT—skin cancer	5.8e-05	7.82e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Innate Immune System—HRAS—skin cancer	5.78e-05	7.79e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—BRAF—skin cancer	5.76e-05	7.76e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—PTGER4—skin cancer	5.74e-05	7.74e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling by GPCR—HRAS—skin cancer	5.71e-05	7.69e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—NRAS—skin cancer	5.68e-05	7.65e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Disease—KRAS—skin cancer	5.66e-05	7.63e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Metabolism—PTGS2—skin cancer	5.65e-05	7.61e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—NRAS—skin cancer	5.6e-05	7.54e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Adaptive Immune System—HRAS—skin cancer	5.55e-05	7.48e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Innate Immune System—IL6—skin cancer	5.53e-05	7.45e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—PTGS2—skin cancer	5.46e-05	7.36e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling by GPCR—IL6—skin cancer	5.46e-05	7.36e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—NRAS—skin cancer	5.37e-05	7.24e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling by GPCR—KRAS—skin cancer	5.35e-05	7.21e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling by GPCR—KRAS—skin cancer	5.27e-05	7.1e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—NRAS—skin cancer	5.25e-05	7.07e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—KRAS—skin cancer	5.24e-05	7.05e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Immune System—HRAS—skin cancer	5.21e-05	7.02e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—FOXO4—skin cancer	5.19e-05	6.99e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—NRAS—skin cancer	5.17e-05	6.96e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—KRAS—skin cancer	5.14e-05	6.92e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—FOXO4—skin cancer	5.07e-05	6.83e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—NRAS—skin cancer	5.04e-05	6.79e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Immune System—IL6—skin cancer	4.99e-05	6.72e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ENO2—skin cancer	4.95e-05	6.67e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—NRAS—skin cancer	4.92e-05	6.62e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—KRAS—skin cancer	4.89e-05	6.59e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—KRAS—skin cancer	4.82e-05	6.49e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Disease—HRAS—skin cancer	4.81e-05	6.48e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—BRAF—skin cancer	4.74e-05	6.38e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—KRAS—skin cancer	4.62e-05	6.23e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—BRAF—skin cancer	4.62e-05	6.23e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—NRAS—skin cancer	4.61e-05	6.21e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Disease—IL6—skin cancer	4.61e-05	6.21e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—NRAS—skin cancer	4.6e-05	6.2e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—BRAF—skin cancer	4.6e-05	6.19e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Metabolism—PTGS2—skin cancer	4.57e-05	6.16e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—TP53—skin cancer	4.57e-05	6.15e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling by GPCR—HRAS—skin cancer	4.55e-05	6.13e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—KRAS—skin cancer	4.52e-05	6.08e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling by GPCR—HRAS—skin cancer	4.48e-05	6.04e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—HRAS—skin cancer	4.45e-05	5.99e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—KRAS—skin cancer	4.45e-05	5.99e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Hemostasis—HRAS—skin cancer	4.37e-05	5.88e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling by GPCR—IL6—skin cancer	4.35e-05	5.86e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—KRAS—skin cancer	4.34e-05	5.84e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Cell Cycle—TP53—skin cancer	4.31e-05	5.8e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling by GPCR—IL6—skin cancer	4.29e-05	5.78e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Developmental Biology—IL6—skin cancer	4.26e-05	5.74e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—NRAS—skin cancer	4.25e-05	5.72e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—KRAS—skin cancer	4.23e-05	5.7e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—HRAS—skin cancer	4.16e-05	5.6e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—HRAS—skin cancer	4.09e-05	5.51e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TERT—skin cancer	4.07e-05	5.48e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Immune System—IL6—skin cancer	3.98e-05	5.36e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—KRAS—skin cancer	3.97e-05	5.34e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—KRAS—skin cancer	3.96e-05	5.34e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—HRAS—skin cancer	3.93e-05	5.29e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Immune System—IL6—skin cancer	3.92e-05	5.28e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	3.87e-05	5.22e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—HRAS—skin cancer	3.84e-05	5.17e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—HRAS—skin cancer	3.78e-05	5.09e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Innate Immune System—IL6—skin cancer	3.76e-05	5.07e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—PTGS2—skin cancer	3.71e-05	5e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—HRAS—skin cancer	3.69e-05	4.96e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—NRAS—skin cancer	3.67e-05	4.95e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Disease—IL6—skin cancer	3.67e-05	4.95e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—KRAS—skin cancer	3.66e-05	4.93e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—NRAS—skin cancer	3.62e-05	4.87e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Disease—IL6—skin cancer	3.62e-05	4.87e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—HRAS—skin cancer	3.6e-05	4.85e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling by GPCR—IL6—skin cancer	3.53e-05	4.75e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—TP53—skin cancer	3.53e-05	4.75e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TERT—skin cancer	3.46e-05	4.67e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling by GPCR—IL6—skin cancer	3.44e-05	4.64e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—NRAS—skin cancer	3.42e-05	4.61e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TERT—skin cancer	3.39e-05	4.56e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—HRAS—skin cancer	3.37e-05	4.54e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—HRAS—skin cancer	3.37e-05	4.54e-05	CbGpPWpGaD
Isoprenaline—PIK3R3—Signaling Pathways—IL6—skin cancer	3.23e-05	4.35e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Immune System—IL6—skin cancer	3.22e-05	4.34e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—BRAF—skin cancer	3.22e-05	4.34e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—KRAS—skin cancer	3.16e-05	4.26e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—NRAS—skin cancer	3.13e-05	4.21e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—KRAS—skin cancer	3.11e-05	4.19e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—HRAS—skin cancer	3.11e-05	4.19e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—NRAS—skin cancer	2.98e-05	4.01e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Disease—IL6—skin cancer	2.98e-05	4.01e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—KRAS—skin cancer	2.95e-05	3.97e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—NRAS—skin cancer	2.92e-05	3.93e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—NRAS—skin cancer	2.91e-05	3.91e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—NRAS—skin cancer	2.89e-05	3.89e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—ERCC2—skin cancer	2.88e-05	3.87e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—NRAS—skin cancer	2.86e-05	3.85e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—TP53—skin cancer	2.81e-05	3.78e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—TP53—skin cancer	2.77e-05	3.73e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—BRAF—skin cancer	2.74e-05	3.7e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—KRAS—skin cancer	2.69e-05	3.63e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—HRAS—skin cancer	2.69e-05	3.62e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—BRAF—skin cancer	2.68e-05	3.61e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—HRAS—skin cancer	2.65e-05	3.57e-05	CbGpPWpGaD
Isoprenaline—PIK3R2—Signaling Pathways—IL6—skin cancer	2.57e-05	3.46e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—KRAS—skin cancer	2.56e-05	3.45e-05	CbGpPWpGaD
Isoprenaline—ADRBK1—Signaling Pathways—IL6—skin cancer	2.53e-05	3.41e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—KRAS—skin cancer	2.51e-05	3.38e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—HRAS—skin cancer	2.51e-05	3.37e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—KRAS—skin cancer	2.5e-05	3.37e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—KRAS—skin cancer	2.49e-05	3.35e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—KRAS—skin cancer	2.46e-05	3.31e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling by GPCR—IL6—skin cancer	2.4e-05	3.23e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—HRAS—skin cancer	2.29e-05	3.08e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—TP53—skin cancer	2.28e-05	3.07e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—TP53—skin cancer	2.22e-05	2.99e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Immune System—IL6—skin cancer	2.19e-05	2.95e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—HRAS—skin cancer	2.18e-05	2.93e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—HRAS—skin cancer	2.14e-05	2.88e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—HRAS—skin cancer	2.13e-05	2.86e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—HRAS—skin cancer	2.11e-05	2.85e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—HRAS—skin cancer	2.09e-05	2.81e-05	CbGpPWpGaD
Isoprenaline—PIK3R1—Signaling Pathways—IL6—skin cancer	2.08e-05	2.81e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling by GPCR—IL6—skin cancer	2.04e-05	2.75e-05	CbGpPWpGaD
Isoprenaline—ADRB3—Signaling Pathways—IL6—skin cancer	2.03e-05	2.74e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—NRAS—skin cancer	2.02e-05	2.73e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Disease—IL6—skin cancer	2.02e-05	2.72e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling by GPCR—IL6—skin cancer	2e-05	2.69e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—KRAS—skin cancer	1.74e-05	2.35e-05	CbGpPWpGaD
Isoprenaline—CYP1A1—Metabolism—PTGS2—skin cancer	1.73e-05	2.32e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—NRAS—skin cancer	1.72e-05	2.32e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—NRAS—skin cancer	1.69e-05	2.27e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—TP53—skin cancer	1.55e-05	2.08e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—KRAS—skin cancer	1.48e-05	2e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—HRAS—skin cancer	1.48e-05	1.99e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—KRAS—skin cancer	1.45e-05	1.96e-05	CbGpPWpGaD
Isoprenaline—MAPK1—Signaling Pathways—IL6—skin cancer	1.42e-05	1.91e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—TP53—skin cancer	1.32e-05	1.78e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—TP53—skin cancer	1.29e-05	1.74e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—HRAS—skin cancer	1.26e-05	1.7e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—HRAS—skin cancer	1.23e-05	1.66e-05	CbGpPWpGaD
Isoprenaline—ADRB1—Signaling Pathways—IL6—skin cancer	1.21e-05	1.63e-05	CbGpPWpGaD
Isoprenaline—ADRB2—Signaling Pathways—IL6—skin cancer	1.18e-05	1.59e-05	CbGpPWpGaD
